Literature DB >> 3719529

Aspergillus sinusitis in cancer patients.

A F Viollier, D E Peterson, C A De Jongh, K A Newman, W C Gray, J C Sutherland, M A Moody, S C Schimpff.   

Abstract

Paranasal sinusitis occurred in 52 immunosuppressed cancer patients treated over 5 years at the University of Maryland Cancer Center. Twenty-one patients had aspergillus sinusitis; Aspergillus sp, including flavus and niger were directly recovered from sinus in 19 of the 21 infections. Two other patients with sinus involvement and positive nose cultures for Aspergillus flavus or fumigatus and microbiologically documented pulmonary aspergillosis were considered clinically, although not microbiologically, documented. Predisposing factors for aspergillus sinusitis during the 60 days prior to infection diagnosis were granulocyte count less than 500 microliter (mean duration, 42 days versus 14 days for sinusitis of other etiology; P less than 0.001), prolonged hospitalization (mean duration, 22 days versus 14 days for patients with nonfungal sinusitis; P less than 0.001), and prolonged antibiotic therapy (mean duration, 22 days versus 9 days; P less than 0.001). Treatment with amphotericin B was initially successful for 18 of 21 patients; however, 11 of 18 patients had infection recurrence that always developed at time of tumor exacerbation and reinstitution or intensification of chemotherapy. These findings suggest that aspergillus sinusitis in cancer patients is seen in association with prolonged neutropenia and antibiotic therapy, is amenable to therapy, but tends to recur with relapse of malignancy.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3719529     DOI: 10.1002/1097-0142(19860715)58:2<366::aid-cncr2820580228>3.0.co;2-v

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

1.  Invasive aspergillosis of the nose and paranasal sinuses in immunocompromised children.

Authors:  C Rotstein
Journal:  CMAJ       Date:  1988-08-15       Impact factor: 8.262

Review 2.  Fungal infections of the immunocompromised host: clinical and laboratory aspects.

Authors:  C E Musial; F R Cockerill; G D Roberts
Journal:  Clin Microbiol Rev       Date:  1988-10       Impact factor: 26.132

Review 3.  Strategies in prevention of invasive pulmonary aspergillosis in immunosuppressed or neutropenic patients.

Authors:  J Beyer; S Schwartz; V Heinemann; W Siegert
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

Review 4.  Nosocomial aspergillosis: environmental microbiology, hospital epidemiology, diagnosis and treatment.

Authors:  T J Walsh; D M Dixon
Journal:  Eur J Epidemiol       Date:  1989-06       Impact factor: 8.082

Review 5.  Aspergillus fumigatus and aspergillosis.

Authors:  J P Latgé
Journal:  Clin Microbiol Rev       Date:  1999-04       Impact factor: 26.132

Review 6.  Aspergillosis.

Authors:  G P Bodey; S Vartivarian
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-05       Impact factor: 3.267

7.  Aerosol amphotericin B is effective for prophylaxis and therapy in a rat model of pulmonary aspergillosis.

Authors:  H J Schmitt; E M Bernard; M Häuser; D Armstrong
Journal:  Antimicrob Agents Chemother       Date:  1988-11       Impact factor: 5.191

Review 8.  Use of amphotericin B aerosols for the prevention of pulmonary aspergillosis.

Authors:  J Beyer; S Schwartz; G Barzen; G Risse; K Dullenkopf; C Weyer; W Siegert
Journal:  Infection       Date:  1994 Mar-Apr       Impact factor: 3.553

9.  Aspergillosis of the sphenoid sinus simulating a pituitary tumor.

Authors:  J Larrañaga; J Fandiño; J Gomez-Bueno; D Rodriguez; J Gonzalez-Carrero; C Botana
Journal:  Neuroradiology       Date:  1989       Impact factor: 2.804

10.  Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).

Authors:  Sabine Mousset; Dieter Buchheidt; Werner Heinz; Markus Ruhnke; Oliver A Cornely; Gerlinde Egerer; William Krüger; Hartmut Link; Silke Neumann; Helmut Ostermann; Jens Panse; Olaf Penack; Christina Rieger; Martin Schmidt-Hieber; Gerda Silling; Thomas Südhoff; Andrew J Ullmann; Hans-Heinrich Wolf; Georg Maschmeyer; Angelika Böhme
Journal:  Ann Hematol       Date:  2013-09-12       Impact factor: 3.673

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.